The Clinical Core (CC) maintains our Longitudinal Cohort (LC), an ethnically and demographically diverse cohort which is the central scientific resource of the UCD ADC. The CC supports the research mission of the ADC to assess how various risk and protective conditions differentially affect cognitive trajectories across the spectrum of cognitive ability. The Core has achieved target enrollment in the LC (n ~530) and now has 2 or more visits on 88% of participants;approximately one-half of LC participants are of minority ethnicity, generally African American or Hispanic. In order to facilitate study of early AD and clinical transitions, about 50% of the LC is cognitively normal, 20% MCI. and 30% demented (59% of whom were non-demented at entry). The CC recruits participants primarily through direct, outreach based community recruitment, and also through ADC clinics. Recruitment now focuses on replenishing the cohort and meeting particular needs of associated scientific projects. It works closely with the Education and Information Transfer Core on recruitment and retention of the LC. The CC consents, evaluates participants in the LC. obtains autopsy preconsents and annual follow-up. The Core provides reliable and valid diagnoses for each participant. It implements standardized clinical data collection protocols, obtaining clinical data including all elements of the UDS. In concert with the Neuropathology Core, it arranges collection of biospecimens (e.g. plasma. DNA. RNA) and works closely with the Neuroimaging Core to obtain research MRI and other brain imaging studies. In addition, it coordinates, enables and monitors the collection of additional data that are crucial to a variety of thematically connected, independent research projects supported by the ADC. Because the Core is so tightly, and synergistically. integrated with independent projects, all participants in the LC also participate in a variety of R01s. The Core implements numerous procedures to maintain data quality and reliability, including monthly clinicopathological case conference (conducted with the Neuropathology Core). The Core supports recruitment for studies by ADC investigators, including pilot studies. The Core maintains a Clinical Trials Unit that carries out industry and academically sponsored diagnostic and treatment trials.
The CC aims to advance our understanding of how various risk factors and protective conditions differentially affect cognitive trajectories across the spectrum of cognitive aging in our ethnically-diverse LC. Understanding the factors which accelerate or protect against cognitive decline could foster healthy brain aging and have a major impact on the public health. The CC supports a variety of research projects relevant to advances in the early detection, diagnosis. etioloy and optimal treatment of AD and dementia.
|Rueda, Alicia D; Lau, Karen M; Saito, Naomi et al. (2015) Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement 11:1080-9|
|Caroli, Anna; Prestia, Annapaola; Wade, Sara et al. (2015) Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Dis Assoc Disord 29:101-9|
|Mah, Linda; Binns, Malcolm A; Steffens, David C et al. (2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry 23:466-76|
|Dmitrieva, Natalia O; Fyffe, Denise; Mukherjee, Shubhabrata et al. (2015) Demographic characteristics do not decrease the utility of depressive symptoms assessments: examining the practical impact of item bias in four heterogeneous samples of older adults. Int J Geriatr Psychiatry 30:88-96|
|Sisco, Shannon; Gross, Alden L; Shih, Regina A et al. (2015) The role of early-life educational quality and literacy in explaining racial disparities in cognition in late life. J Gerontol B Psychol Sci Soc Sci 70:557-67|
|Bertens, Daniela; Knol, Dirk L; Scheltens, Philip et al. (2015) Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement 11:511-22|
|Melrose, Rebecca J; Brewster, Paul; Marquine, María J et al. (2015) Early life development in a multiethnic sample and the relation to late life cognition. J Gerontol B Psychol Sci Soc Sci 70:519-31|
|Teng, Edmond; Chow, Nicole; Hwang, Kristy S et al. (2015) Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord 39:154-66|
|Epstein, Noam U; Guo, Rong; Farlow, Martin R et al. (2014) Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. Drugs Aging 31:125-9|
|Qiu, Yue; Li, Liang; Zhou, Tian-yan et al. (2014) Alzheimer's disease progression model based on integrated biomarkers and clinical measures. Acta Pharmacol Sin 35:1111-20|
Showing the most recent 10 out of 579 publications